As of 02 March 2026 the Health Technology Assessment Council has completed the evidence appraisal on the assessment of Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) Mutation Test for the diagnosis of EGFR mutations in patients with non-small cell lung cancer (NSCLC), for possible government financing. The HTA Council hereby releases its preliminary continue reading : HTA Council Preliminary Recommendation on Epidermal growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) Mutation Tests for the Diagnosis of EGFR Mutations in Patients with Non-small cell Lung Cancer (NSCLC)
HTA Council Preliminary Recommendation on Erlotinib, Gefitinib, and Afatinib for the Treament of Epidermal growth Factor Receptor (EGFR)-positive Non-small Cell Lung Cancer (NSCLC)
As of 19 February 2026, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of Erlotinib, Gefitinib, and Afatinib for the treatment of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), for government financing. The HTA Council hereby releases its preliminary recommendation on the said health technologies for stakeholder continue reading : HTA Council Preliminary Recommendation on Erlotinib, Gefitinib, and Afatinib for the Treament of Epidermal growth Factor Receptor (EGFR)-positive Non-small Cell Lung Cancer (NSCLC)